Cardiac safety and efficacy of concomitant liposomal doxorubicin, docetaxel, and trastuzumab as neoadjuvant therapy in HER2-overexpressing breast cancer: A retrospective analysis

被引：0
|
作者：
Brunner, Christine
Jaeger, Thomas
Suppan, Christoph
Mueller-Holzner, Elisabeth
Jasarevic, Zerina
Balic, Marija
Goebel, Georg
Marth, Christian
Stoeger, Herbert
Samonigg, Hellmut
Hubalek, Michael
Lang, Alois
机构：
[1] Dept Gynecol & Obstet, Innsbruck, Austria
[2] LKH Feldkirch, Feldkirch, Austria
[3] Med Univ Graz, Dept Internal Med, Graz, Austria
[4] Med Univ Innsbruck, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria
[5] Breast Canc Ctr Vorarlberg, Feldkirch, Austria
[6] Med Univ Graz, Graz, Austria
[7] Med Univ Innsbruck, Dept Med Stat Informat & Hlth Oecon, A-6020 Innsbruck, Austria
[8] Med Univ Graz, Dept Med Oncol, Graz, Austria
[9] Med Univ Innsbruck, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria
[10] Acad Teaching Hosp, Feldkirch, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
583
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Longterm survival benefit of neoadjuvant liposomal doxorubicin, docetaxel, and trastuzumab in HER2-overexpressing breast cancer: A retrospective and multicenter analysis.
    Brunner, Christine
    Wieser, Verena
    Jaeger, Thomas
    Lang, Alois
    Stoger, Herbert
    Suppan, Christoph
    Goebel, Georg
    Soleiman, Afschin
    Egle, Daniel
    Marth, Christian
    Hubalek, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Efficacy and cardiac safety in neoadjuvant treatment of Her2 positive breast cancer with concomitant nonpegylated liposomal doxorubicin, docetaxel and dual blockade with trastuzumab and pertuzumab: A retrospective analysis
    Egle, D.
    Hubalek, M.
    Hager, C.
    Poyssl, C.
    Lang, A.
    Jaeger, T.
    Volgger, B.
    Abdel-Azim, S.
    Tiechl, J.
    Angerer, J.
    Marth, C.
    CANCER RESEARCH, 2016, 76
  • [3] Neoadjuvant treatment of HER2 positive breast cancer with concomitant nonpegylated liposomal doxorubicin (NPLD), docetaxel and dual blockade with trastuzumab and pertuzumab: A retrospective analysis of pCR and cardiac safety.
    Egle, Daniel
    Brunner, Christine
    Czech, Theresa
    Jaeger, Thomas
    Lang, Alois
    Hager, Christopher
    Poisl, Clemens
    Volgger, Birgit
    Marth, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-Overexpressing metastatic breast cancer
    Andreopoulou, Eleni
    Gaiotti, Darci
    Kim, Eugene
    Volm, Matthew
    Oratz, Ruth
    Freedberg, Robin
    Downey, Andrea
    Vogel, Charles L.
    Chia, Stephen
    Muggia, Franco
    CLINICAL BREAST CANCER, 2007, 7 (09) : 690 - 696
  • [5] Neoadjuvant chemotherapy with non-pegylated liposomal doxorubicin, docetaxel and trastuzumab in HER-2/neu overexpressing breast cancer
    Schippinger, Walter
    Lileg, Brigitte
    Ploner, Ferdinand
    Weitzer, Werner
    Bauemhofer, Thomas
    Samonigg, Hellmut
    ANNALS OF ONCOLOGY, 2007, 18 : 166 - 166
  • [6] Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
    Clara Natoli
    Patrizia Vici
    Isabella Sperduti
    Antonino Grassadonia
    Giancarlo Bisagni
    Nicola Tinari
    Andrea Michelotti
    Germano Zampa
    Stefania Gori
    Luca Moscetti
    Michele De Tursi
    Michele Panebianco
    Maria Mauri
    Ilaria Ferrarini
    Laura Pizzuti
    Corrado Ficorella
    Riccardo Samaritani
    Lucia Mentuccia
    Stefano Iacobelli
    Teresa Gamucci
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 1229 - 1240
  • [7] Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
    Natoli, Clara
    Vici, Patrizia
    Sperduti, Isabella
    Grassadonia, Antonino
    Bisagni, Giancarlo
    Tinari, Nicola
    Michelotti, Andrea
    Zampa, Germano
    Gori, Stefania
    Moscetti, Luca
    De Tursi, Michele
    Panebianco, Michele
    Mauri, Maria
    Ferrarini, Ilaria
    Pizzuti, Laura
    Ficorella, Corrado
    Samaritani, Riccardo
    Mentuccia, Lucia
    Iacobelli, Stefano
    Gamucci, Teresa
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (07) : 1229 - 1240
  • [8] Combined neoadjuvant weekly paclitaxel and trastuzumab for HER2-overexpressing breast cancer
    Horiguchi, J.
    Koibuchi, Y.
    Rokutanda, N.
    Nagaoka, R.
    Kikuchi, M.
    Sato, A.
    Ishikawa, Y.
    Odawara, H.
    Iino, Y.
    Takeyoshi, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Mechanisms of resistance to trastuzumab as neoadjuvant therapy in women with HER2-overexpressing operable breast cancer.
    Jinno, Hiromitsu
    Sato, Tomomi
    Hayashida, Tetsu
    Takahashi, Maiko
    Hirose, Shigemichi
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer
    Tian, Chunyu
    Wang, Minghui
    Liu, Hancheng
    Liu, Jianping
    Xu, Mengze
    Ma, Lihui
    IRISH JOURNAL OF MEDICAL SCIENCE, 2023, 192 (03) : 1041 - 1049
12345